DelMar Pharmaceuticals Announces Proposed Public Offering Of Common Stock And Warrants April 12, 2017 • 4:22 PM EDT
DelMar Pharmaceuticals Provides VAL-083 Updates from the Ongoing American Association for Cancer Research (AACR) Annual Meeting April 5, 2017 • 8:30 AM EDT
DelMar Pharmaceuticals Announces Abstract Presentations for the American Association for Cancer Research (AACR) Annual Meeting in April 2017 March 28, 2017 • 8:30 AM EDT
DelMar Pharmaceuticals to Participate in Key Opinion Leader Luncheon on Glioblastoma Multiforme Featuring Dr. James Perry, MD March 2, 2017 • 8:30 AM EST
DelMar Pharmaceuticals Announces Dosing of the First Patient in Phase Two Clinical Trial of VAL-083 for MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM) February 13, 2017 • 8:40 AM EST
DelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2017 Financial Results February 13, 2017 • 8:15 AM EST
DelMar Pharmaceuticals and MD Anderson Initiate New Phase Two Clinical Trial of VAL-083 for MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM) January 25, 2017 • 8:30 AM EST
DelMar Pharmaceuticals Receives Additional Non-Dilutive Funding from the Government of Canada to Support Expanded Research with Lead Product Candidate VAL-083 January 9, 2017 • 8:30 AM EST
DelMar Pharmaceuticals Receives Notice of Allowance from the US Patent and Trademark Office for Key Patent for VAL-083 December 14, 2016 • 8:00 AM EST
DelMar Pharmaceuticals Delivers an Address and Presents an Overview of Upcoming GBM Trials with VAL-083 at the CNS Anticancer Drug Discovery Development Conference and Society for NeuroOncology Annual Meeting November 21, 2016 • 8:30 AM EST